Category: Regulatory DisclosuresBy adminJuly 9, 2020 Author: admin https://ramedapharma-ir.com Post navigationPreviousPrevious post:Rameda commences manufacture of “Anviziram” Tablets the Generic Equivalent of Japanese antiviral Avigan for treatment of Covid-19 patients and receives approval from Egyptian Drug Authority to manufacture RemedsivirNextNext post:Disclosure to EGX on BOD minutesRelated PostsRameda Announces New Chairman and Additions to its Board of DirectorsJune 3, 2026Rameda Initiates First Acquisition of 2025July 7, 2025Record Dividend Distribution DisclosureJuly 7, 2025BOD-Shareholding-Structure-2024April 15, 2024The invitation to shareholders for the AGMMarch 31, 2024RetractionMarch 24, 2024
